<DOC>
	<DOCNO>NCT01127503</DOCNO>
	<brief_summary>This exploratory clinical investigation . The objective study evaluate safety , steady-state pharmacokinetics , efficacy metyrosine ( Demser® ) treatment psychosis patient velocardiofacial syndrome ( VCFS ) .</brief_summary>
	<brief_title>Metyrosine ( Demser® ) Treatment Psychotic Disorders Patients With Velocardiofacial Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<mesh_term>Facial Paralysis</mesh_term>
	<mesh_term>alpha-Methyltyrosine</mesh_term>
	<criteria>Key 1 . Females childbearing potential risk pregnancy study . 2 . Genetically confirm diagnosis VCFS time screen . 3 . Must one follow Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ( DSMIV TR ) diagnose ( applicable base upon clinical assessment ) : schizophrenia , schizoaffective disorder , psychosis otherwise specify ( NOS ) , bipolar disorder , mood disorder psychotic feature . 4 . A total PANSS composite score &gt; 65 . 5 . Willing discontinue psychotropic medication . Key 1 . Evidence acute suicidality . 2 . Known observe clinically significant cardiovascular , pulmonary , renal , hepatic , gastrointestinal disorder ; clinically significant psychiatric/neurological sleep disorder DSMIVTR criterion ; endocrine , hematological metabolic disease . 3 . Full scale IQ le 50 . 4 . Pregnancy . 5 . Not use reliable mean contraception . 6 . Systolic blood pressure ≤110 mm/Hg ≥160 mm/Hg , diastolic blood pressure ≤60 mm/Hg ≥90 mm/Hg , clinically symptomatic orthostatic change . 7 . QTcF &gt; 450 msec , PR &gt; 250 msec , QRS &gt; 110 msec ECG . 8 . History seizure disorder .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Patients velocardiofacial syndrome psychosis</keyword>
</DOC>